News
GOSS
0.7083
-3.97%
-0.0293
Weekly Report: what happened at GOSS last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at GOSS last week (0408-0412)?
Weekly Report · 04/15 09:24
Weekly Report: what happened at GOSS last week (0401-0405)?
Weekly Report · 04/08 09:25
GOSSAMER BIO INC <GOSS.O>: WEDBUSH ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $4
Reuters · 04/05 11:26
Gossamer Bio Coverage Assumed by Wedbush at Outperform
Dow Jones · 04/05 09:07
Gossamer Bio Price Target Announced at $4.00/Share by Wedbush
Dow Jones · 04/05 09:07
Wedbush Assumes Gossamer Bio at Outperform, Announces Price Target of $4
Benzinga · 04/05 08:57
Weekly Report: what happened at GOSS last week (0325-0329)?
Weekly Report · 04/01 09:25
Gossamer Bio: Statement of changes in beneficial ownership of securities
Press release · 03/29 02:21
Gossamer Bio Price Target Maintained With a $15.00/Share by Piper Sandler
Dow Jones · 03/27 16:53
Gossamer Bio Is Maintained at Overweight by Piper Sandler
Dow Jones · 03/27 16:53
Piper Sandler Maintains Overweight on Gossamer Bio, Maintains $15 Price Target
Benzinga · 03/27 16:43
Buy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment Landscape
TipRanks · 03/27 13:55
Gossamer Bio (GOSS) Receives a Buy from Piper Sandler
TipRanks · 03/27 11:06
Weekly Report: what happened at GOSS last week (0318-0322)?
Weekly Report · 03/25 09:26
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)
3 analysts have maintained Buy ratings on Diamedica Therapeutics, Gossamer Bio and Vor Biopharma. The Healthcare sector has 3 of the top 10 most bullish stocks on The Street. The 3 stocks have a combined market value of $1.2 billion.
TipRanks · 03/21 13:00
Weekly Report: what happened at GOSS last week (0311-0315)?
Weekly Report · 03/18 09:25
Piper Sandler Sticks to Its Buy Rating for Gossamer Bio (GOSS)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Gossamer Bio (GOSS) with a price target of $15.00. The company’s shares closed yesterday at $1.40. Rahimi is a 4-star analyst with an average return of 9.9% and a 41.00% success rate. The analyst consensus on GOSSamer Bio is a Strong Buy with a 417.86% upside.
TipRanks · 03/13 10:55
Gossamer Bio Welcomes New Board Members, Enhances Leadership
TipRanks · 03/12 20:13
Weekly Report: what happened at GOSS last week (0304-0308)?
Weekly Report · 03/11 09:25
More
Webull provides a variety of real-time GOSS stock news. You can receive the latest news about Gossamer Bio through multiple platforms. This information may help you make smarter investment decisions.
About GOSS
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).